Researchers investigated the role of interleukin-1 inhibition in improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes.
The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
Results of an investigational US pilot study have shown that a proprietary bioelectronic microregulator device, manufactured by SetPoint Medical, can benefit patients with rheumatoid arthritis.
Upadacitinib monotherapy resulted in improvements in clinical and functional outcomes vs continuing methotrexate in a population of methotrexate inadequate-responders with active RA.
Study compared efficacy and safety of filgotinib with and without methotrexate in patients with rheumatoid arthritis who were naive to methotrexate therapy.
In patients with rheumatoid arthritis treated with anti-inflammatory medications, long-term persistent pain was found to be common and may be predicted by higher levels of disability and a history of smoking.
The use of abatacept as an initial bDMARD for the treatment of patients with rheumatoid arthritis is associated with a slightly elevated risk for cancer overall.